Medscape

Managing Chronic Hepatitis B: Updated Guideline Expands Options

Joint AASLD/IDSA practice recommendations reflect new data on prevention, treatment, and surveillance of chronic hepatitis B, ...

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated ...
India Today on MSN

Can a mother with Hepatitis B affect her baby? Doctors explain the risks and prevention

Hepatitis B during pregnancy can pass to the baby, but it is preventable. Early testing, timely treatment, and newborn ...
Mississippi Today

Sen. Chassaniol says she is likely to kill prison health care reforms

Legislative proposals about prison health care follow investigative reports from Mississippi Today and other news outlets on ...
Pharmabiz

GSK’s bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B

GSK’s bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B: London, UK Friday, February 27, 2026, 09:00 Hrs [IST] ...

Diabetes, HIV, Hepatitis C must be treated as national emergencies, NA body emphasises

The Standing Committee on National Health Services, Regulations and Coordination (NHSR&C) emphasised that diabetes, HIV, ...

Worst treatment disaster in the history of the NHS inquiry to close

The inquiry into what has been dubbed the worst treatment disaster in the history of the NHS is to officially close in March.
The American Journal of Managed Care

Unmasking Hepatitis B Risks in Long-Acting ART: Laurence Brunet, PhD, and Gerald Pierone, MD

At CROI 2026, experts warned that missing HBV screening risks reactivation during HIV therapy switches.

Increase in registration fee for STD services at Mobile County Health Department

The post says the fee has increased from $15 to $20.

Atea Pharmaceuticals, Inc.: Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuti ...

ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative

Since the program’s authorization in May 2025, between prior repurchases and the ASR, ADMA will have repurchased approximately $160 million of its common stock to date. Management believes these ...